For example, the ZFN nuclease domain has been modified to improve ZFN activity and Dinaciclib CDK inhibitor specificity. Additionally, modifying the culture temperature caused a significant increase in ZFN activity. Furthermore, our group recently reported a simple method to enrich cells that contain ZFN-induced gene disruptions. Given that these simple methods to improve the ZFN function have facilitated the use of ZFNs, the identification of small molecules that increase ZFN function should likewise efficiently facilitate the application of ZFNs. However, such small molecules have yet to be identified. It has been observed that ZFN protein levels are directly correlated with ZFN function. Culturing the cells at low temperature increases ZFN function at least in part because ZFN protein levels increase. We also observed that cell populations that are enriched with gene-disrupted cells have high ZFN levels as compared to control cells. Recently, direct delivery of ZFN proteins has been shown to be safer associated with negligible offtarget effects. These ZFN proteins could penetrate the cells without any additional cell-penetrating peptide sequences and were able to transduce into several cell types including those that are hard to transfect. However, due to degradation of the delivered protein, it was necessary to treat the cells several times with the ZFN protein to obtain significant genetic modifications. Thus, we postulated that stabilizing the ZFN protein could enhance ZFN function. However, ZFN stability and the factors that affect it have yet to be investigated. Proteins are in a continual state of flux between synthesis and degradation in a cell. The ubiquitin proteasome pathway is one of the major cellular regulatory mechanisms involved in protein turnover and half-life. UPP plays a key role in eliminating intracellular proteins in eukaryotes, especially misfolded cellular proteins. During ubiquitination, a post-translational modification that targets proteins for degradation by the 26S proteasome, multiple ubiquitin molecules are covalently attached to targeted proteins. This process is catalyzed by a three step cascade mechanism, which involves a ubiquitin activating enzyme, a ubiquitin conjugating enzyme, and a ubiquitin ligase. E1 activates ubiquitin molecules by the formation of an ATP-dependent thiol ester bond between the C-terminus of ubiquitin and the active cysteine site of the E1 enzyme. Activated ubiquitin is transferred to the active cysteine site of the E2 enzyme. Ultimately, E3 catalyzes the transfer of ubiquitin molecules to a lysine residue, ultimately forming polyubiquitin chains on the protein that is 
destined for degradation. Finally, ubiquitinated proteins are directed into the 20S core proteolytic KRX-0401 chamber in an ATP-dependent manner for 26S proteasomal degradation. Small chemical molecules, such as synthetic, cell-permeable peptide aldehydes that form covalent adducts with the 20S proteasome and inhibit its peptidase activities, have been developed. Synthetic proteasome inhibitors are peptide aldehydes which are broadly used as inhibitors for both Serine and Cysteine proteases. Several proteasome inhibitors that can enter the cells and block protein degradation pathway have been identified. Among them, the proteasome inhibitor MG132 is the most widely used commercial inhibitor for regulating the UPP. Because ZFN levels are directly proportional to ZFN activity.